164 related articles for article (PubMed ID: 11106117)
1. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.
Khan TS; Imam H; Juhlin C; Skogseid B; Gröndal S; Tibblin S; Wilander E; Oberg K; Eriksson B
Ann Oncol; 2000 Oct; 11(10):1281-7. PubMed ID: 11106117
[TBL] [Abstract][Full Text] [Related]
2. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.
Baudin E; Pellegriti G; Bonnay M; Penfornis A; Laplanche A; Vassal G; Schlumberger M
Cancer; 2001 Sep; 92(6):1385-92. PubMed ID: 11745214
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy in advanced adrenocortical carcinoma.
Fassnacht M; Terzolo M; Allolio B; Baudin E; Haak H; Berruti A; Welin S; Schade-Brittinger C; Lacroix A; Jarzab B; Sorbye H; Torpy DJ; Stepan V; Schteingart DE; Arlt W; Kroiss M; Leboulleux S; Sperone P; Sundin A; Hermsen I; Hahner S; Willenberg HS; Tabarin A; Quinkler M; de la Fouchardière C; Schlumberger M; Mantero F; Weismann D; Beuschlein F; Gelderblom H; Wilmink H; Sender M; Edgerly M; Kenn W; Fojo T; Müller HH; Skogseid B;
N Engl J Med; 2012 Jun; 366(23):2189-97. PubMed ID: 22551107
[TBL] [Abstract][Full Text] [Related]
4. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
Hermsen IG; Fassnacht M; Terzolo M; Houterman S; den Hartigh J; Leboulleux S; Daffara F; Berruti A; Chadarevian R; Schlumberger M; Allolio B; Haak HR; Baudin E
J Clin Endocrinol Metab; 2011 Jun; 96(6):1844-51. PubMed ID: 21470991
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hormone-producing adrenocortical cancer with o,p'DDD and streptozocin.
Eriksson B; Oberg K; Curstedt T; Hemmingsson A; Johansson H; Lindh E; Lindgren PG; Thuomas KA; Wilander E; Akerström G
Cancer; 1987 Apr; 59(8):1398-403. PubMed ID: 2949824
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study.
Bukowski RM; Wolfe M; Levine HS; Crawford DE; Stephens RL; Gaynor E; Harker WG
J Clin Oncol; 1993 Jan; 11(1):161-5. PubMed ID: 8418229
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
8. Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results.
Faggiano A; Leboulleux S; Young J; Schlumberger M; Baudin E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):110-3. PubMed ID: 16402938
[TBL] [Abstract][Full Text] [Related]
9. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
10. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
Berruti A; Terzolo M; Sperone P; Pia A; Della Casa S; Gross DJ; Carnaghi C; Casali P; Porpiglia F; Mantero F; Reimondo G; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Sep; 12(3):657-66. PubMed ID: 16172198
[TBL] [Abstract][Full Text] [Related]
11. [Practical use of o,p'DDD in adrenocortical carcinoma].
Bacchetta J; Droz JP
Bull Cancer; 2005 Mar; 92(3):273-9. PubMed ID: 15820922
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports.
Zidan J; Shpendler M; Robinson E
Am J Clin Oncol; 1996 Jun; 19(3):229-31. PubMed ID: 8638530
[TBL] [Abstract][Full Text] [Related]
13. The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
Hescot S; Paci A; Seck A; Slama A; Viengchareun S; Trabado S; Brailly-Tabard S; Al Ghuzlan A; Young J; Baudin E; Lombès M
Horm Cancer; 2014 Oct; 5(5):312-23. PubMed ID: 25026941
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic chemotherapy for adrenocortical carcinoma.
Dogliotti L; Berruti A; Pia A; Paccotti P; Alì A; Angeli A
Minerva Endocrinol; 1995 Mar; 20(1):105-9. PubMed ID: 7544429
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial.
Redlich A; Boxberger N; Strugala D; Frühwald MC; Leuschner I; Kropf S; Bucsky P; Vorwerk P
Klin Padiatr; 2012 Oct; 224(6):366-71. PubMed ID: 23143764
[TBL] [Abstract][Full Text] [Related]
17. Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma.
Hague RV; May W; Cullen DR
Clin Endocrinol (Oxf); 1989 Jul; 31(1):51-7. PubMed ID: 2574647
[TBL] [Abstract][Full Text] [Related]
18. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
[TBL] [Abstract][Full Text] [Related]
19. Mitotane treatment for adrenocortical carcinoma: an overview.
De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
[TBL] [Abstract][Full Text] [Related]
20. Management of Cushing's syndrome due to ectopic adrenocorticotropin secretion with 1,ortho-1, para'-dichloro-diphenyl-dichloro-ethane: findings in 23 patients from a single center.
Donadille B; Groussin L; Waintrop C; Abbas H; Tenenbaum F; Dugué MA; Coste J; Bertagna X; Bertherat J
J Clin Endocrinol Metab; 2010 Feb; 95(2):537-44. PubMed ID: 20061433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
